Blockade of morphine supersensitivity by an antisense oligodeoxynucleotide targeting the delta opioid receptor (DOR-1)

Life Sci. 1997;60(9):PL155-9. doi: 10.1016/s0024-3205(96)00704-7.

Abstract

An antisense oligodeoxynucleotide (ODN) targeting 20 bases of the coding sequence of the cloned delta opioid receptor (DOR-1), a mismatched ODN (different from the antisense ODN at 4 bases) or saline was administered to 3 groups of CD-1 mice implanted with naltrexone pellets (7.5 mg) for 7 days. Morphine supersensitivity (i.e., increased potency as defined by decreased morphine ED50 values) was observed 24 h after pellet removal (day 8) in mice treated with saline or mismatch ODN, but not in antisense ODN treated mice. Antisense ODN alone had no effect on basal nociceptive thresholds or morphine analgesia but reduced the analgesic potency of the delta, opioid agonist [D-Ala2]deltorphin II. These data suggest that the delta2 opioid receptor system participates in the adaptive changes contributing to increased morphine potency following chronic naltrexone treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analgesics / pharmacology
  • Animals
  • Base Sequence
  • Drug Tolerance / physiology
  • Male
  • Mice
  • Morphine / pharmacology*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / pharmacology*
  • Receptors, Opioid, delta / antagonists & inhibitors*
  • Receptors, Opioid, delta / genetics
  • Receptors, Opioid, delta / physiology

Substances

  • Analgesics
  • Narcotic Antagonists
  • Oligonucleotides, Antisense
  • Receptors, Opioid, delta
  • Naltrexone
  • Morphine